Novavax CEO Erck on Retirement, Covid Vaccines

The transcript discusses the leadership transition at Novavax, with John Jacobs taking over as CEO. It highlights the challenges he will face, including capturing market share in the COVID-19 vaccine market. The discussion covers the outlook for COVID vaccine sales, pricing strategies, and financial planning. Future vaccine development, including a COVID-19 influenza vaccine, is also addressed.

What are the expected pricing strategies for COVID vaccines as they shift to the commercial market?

How does Novavax plan to address the demand for vaccines in low and middle-income countries?

What is the significance of the phase two trial of the COVID-19 influenza vaccine?